3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
2
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Hepatitis, Chronic
1
Hepatitis C
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
BRCA1/2 Mutation
1
Interventions
pembrolizumab
29
Cisplatin
24
Oxaliplatin
22
Irinotecan
22
Fluorouracil
22
Capecitabine
20
Leucovorin
17
Paclitaxel
16
Cyclophosphamide
14
Trastuzumab
12
Nivolumab
11
Carboplatin
11
Gemcitabine
10
Bevacizumab
10
Docetaxel
9
fludarabine
8
aldesleukin
8
S 1 (combination)
8
Ramucirumab
7
130-nm albumin-bound paclitaxel
7
atezolizumab
6
Albumin-Bound Paclitaxel
6
Taxes
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
veliparib
4
tislelizumab
4
spartalizumab
4
dehydroftorafur
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Stomach Neoplasms
×
rocakinogene sifuplasmid
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled